Precision medicine software built from Seven Bridges and Pierian merger
Velsera emerged in 2023 from the combination of Seven Bridges and Pierian, positioning itself in drug discovery, IVD development, and clinical NGS interpretation. The hiring shape—finance-heavy (6 roles) with concentrated director-level placements (5)—reflects post-merger integration work, while active projects centered on FedRAMP authorization, cloud security controls, and Seven Bridges platform implementations for research data commons signal a compliance-first infrastructure posture. Pain-point data confirms internal friction: slow software delivery, reporting inefficiency, and customer churn risk all appear in the top challenges.
Notable leadership hires: Technical Lead
Velsera provides software and professional services for multimodal data harmonization, drug discovery analytics, IVD validation and approval workflows, and clinical NGS interpretation. The company operates across precision medicine and life sciences, serving pharma, biotech, and clinical organizations. Founded in 2023 through a merger, Velsera spans 501–1,000 employees across the United States and India, with headquarters in Charlestown, MA. The technology stack emphasizes AWS, GCP, and Azure infrastructure (EKS, ECS, CloudFormation, Terraform) alongside Java, Python, and Go services, with compliance certifications in FedRAMP, ISO 27001, and ISO 27017.
AWS (EKS, ECS, CloudFormation), GCP, Azure, Java, Python, Go, PostgreSQL, MongoDB, Elasticsearch, Terraform, Ansible, Prometheus, Grafana, Spring Boot, and Jenkins for CI/CD. FedRAMP and ISO 27001/27017 certified.
FedRAMP authorization, cloud security controls, Seven Bridges platform implementations for cancer research data commons and BioData Catalyst, deployment automation, and monitoring strategy implementation.
Other companies in the same industry, closest in size